PMID: 7529341Jan 25, 1995Paper

A prospective evaluation of plasma prostate-specific antigen for detection of prostatic cancer

JAMA : the Journal of the American Medical Association
P H GannM J Stampfer

Abstract

To evaluate the validity of prostate-specific antigen (PSA) in identifying men who subsequently were or were not clinically diagnosed with prostate cancer, assess optimal test cutoff, measure lead time, and estimate relative risks (RRs) associated with discrete PSA levels. Nested case-control study of men providing plasma samples before a 10-year follow-up. The Physicians' Health Study, an ongoing randomized trial that enrolled 22,071 men aged 40 to 84 years in 1982. A total of 366 men (cases) diagnosed with prostate cancer and 1098 men (three controls per case), matched by age, randomly selected from all cohort members at risk at the time of case diagnosis. Sensitivity and specificity for each year of follow-up and for aggressive and nonaggressive cancers separately. At a cutoff of 4.0 ng/mL, sensitivity for the entire 10-year follow-up was 46% for total cases. Sensitivities for detection of total, aggressive, and nonaggressive cancers occurring in the first 4 years were 73%, 87%, and 53%. Overall, specificity was 91% and changed little by year of follow-up. Optimal validity was achieved at a cutoff of 3.3 ng/mL. Estimated mean lead time for all cancers was 5.5 years. Only 40% of cancers detected more than 5 years from baselin...Continue Reading

Associated Clinical Trials

Oct 28, 1999·John Michael Gaziano, MD

Citations

May 2, 2001·Lancet·P FinneU H Stenman
Apr 12, 2003·The Lancet Oncology·James A Talcott
Nov 4, 1995·Lancet·J Waxman, D Sheer
Dec 4, 2008·Asian Journal of Andrology·Nigel Borley, Mark R Feneley
Mar 1, 1997·British Journal of Urology·U H Stenman
May 1, 1995·Cancer Causes & Control : CCC·J W Waterbor, A J Bueschen
Aug 25, 2005·Journal of General Internal Medicine·Brian R Jackson, William L Roberts
Sep 1, 1996·Journal of General Internal Medicine·J B MeigsS J Jacobsen
Jun 8, 2007·Journal of General Internal Medicine·Richard M HoffmanAnn S Hamilton
Jan 4, 2008·Journal of General Internal Medicine·Stephen W MarcellaHomer Wilcox
Oct 21, 1999·Journal of the National Cancer Institute·H B CarterJ D Pearson
Oct 13, 2000·American Journal of Public Health·C B SteeleC T Baker
Feb 7, 2004·BMJ : British Medical Journal·Malcolm Law
May 28, 2004·The New England Journal of Medicine·H Ballentine Carter
Nov 5, 2005·Nature Clinical Practice. Oncology·Richard M MartinJenny Donovan
Jun 15, 2007·International Journal of Epidemiology·Richard M Martin
Apr 3, 2008·Cancer Research·Kimberly A KellyRalph Weissleder
May 29, 2008·Journal of the National Cancer Institute·Sunita R SetlurMark A Rubin
Mar 12, 2009·Journal of the National Cancer Institute·Gerrit DraismaHarry de Koning
Mar 26, 2009·Current Opinion in Urology·George BotchorishviliHans Lilja
Sep 26, 2009·BMJ : British Medical Journal·Benny HolmströmPär Stattin
Feb 6, 2010·The British Journal of General Practice : the Journal of the Royal College of General Practitioners·William Hamilton
Mar 5, 2010·BMC Medical Informatics and Decision Making·Caroline S DorfmanKathryn L Taylor
Apr 22, 2010·Cancer Epidemiology, Biomarkers & Prevention : a Publication of the American Association for Cancer Research, Cosponsored by the American Society of Preventive Oncology·Caroline J SavageAndrew J Vickers
May 7, 2011·Cancer Epidemiology, Biomarkers & Prevention : a Publication of the American Association for Cancer Research, Cosponsored by the American Society of Preventive Oncology·Roman GulatiRuth Etzioni
Nov 22, 2011·World Journal of Urology·Andrew J Vickers, Hans Lilja
Jun 1, 1996·European Journal of Cancer : Official Journal for European Organization for Research and Treatment of Cancer (EORTC) [and] European Association for Cancer Research (EACR)·X FilellaL A Rioja
Aug 26, 1998·European Journal of Cancer : Official Journal for European Organization for Research and Treatment of Cancer (EORTC) [and] European Association for Cancer Research (EACR)·P N PostJ W Coebergh
Mar 13, 2002·European Journal of Cancer : Official Journal for European Organization for Research and Treatment of Cancer (EORTC) [and] European Association for Cancer Research (EACR)·F H Schröder
Aug 5, 2000·Current Opinion in Urology·M R Feneley, A W Partin
Oct 14, 2006·Current Opinion in Urology·N Oakley
Oct 14, 2006·Current Opinion in Urology·U H StenmanP Wu
Apr 7, 2007·Current Opinion in Urology·William G Nelson
Mar 13, 2010·Current Opinion in Urology·Stacy Loeb, William J Catalona
Sep 25, 2001·Comprehensive Therapy·E C Chan
Nov 27, 2002·Journal of Occupational and Environmental Medicine·Paul A MacLennanXiao Cheng Wu
Nov 15, 2000·Clinical Genetics·D J DoukasL B McCullough
Feb 14, 2006·Nature Clinical Practice. Urology·Robert E Reiter, Benjamin Shurtleff

❮ Previous
Next ❯

Related Concepts

Trending Feeds

COVID-19

Coronaviruses encompass a large family of viruses that cause the common cold as well as more serious diseases, such as the ongoing outbreak of coronavirus disease 2019 (COVID-19; formally known as 2019-nCoV). Coronaviruses can spread from animals to humans; symptoms include fever, cough, shortness of breath, and breathing difficulties; in more severe cases, infection can lead to death. This feed covers recent research on COVID-19.

Blastomycosis

Blastomycosis fungal infections spread through inhaling Blastomyces dermatitidis spores. Discover the latest research on blastomycosis fungal infections here.

Nuclear Pore Complex in ALS/FTD

Alterations in nucleocytoplasmic transport, controlled by the nuclear pore complex, may be involved in the pathomechanism underlying multiple neurodegenerative diseases including Amyotrophic Lateral Sclerosis and Frontotemporal Dementia. Here is the latest research on the nuclear pore complex in ALS and FTD.

Applications of Molecular Barcoding

The concept of molecular barcoding is that each original DNA or RNA molecule is attached to a unique sequence barcode. Sequence reads having different barcodes represent different original molecules, while sequence reads having the same barcode are results of PCR duplication from one original molecule. Discover the latest research on molecular barcoding here.

Chronic Fatigue Syndrome

Chronic fatigue syndrome is a disease characterized by unexplained disabling fatigue; the pathology of which is incompletely understood. Discover the latest research on chronic fatigue syndrome here.

Evolution of Pluripotency

Pluripotency refers to the ability of a cell to develop into three primary germ cell layers of the embryo. This feed focuses on the mechanisms that underlie the evolution of pluripotency. Here is the latest research.

Position Effect Variegation

Position Effect Variagation occurs when a gene is inactivated due to its positioning near heterochromatic regions within a chromosome. Discover the latest research on Position Effect Variagation here.

STING Receptor Agonists

Stimulator of IFN genes (STING) are a group of transmembrane proteins that are involved in the induction of type I interferon that is important in the innate immune response. The stimulation of STING has been an active area of research in the treatment of cancer and infectious diseases. Here is the latest research on STING receptor agonists.

Microbicide

Microbicides are products that can be applied to vaginal or rectal mucosal surfaces with the goal of preventing, or at least significantly reducing, the transmission of sexually transmitted infections. Here is the latest research on microbicides.